HEALIUS LIMITED (HLS)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

HLS

HLS - HEALIUS LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 4.61
Index: ASX200 | ASX300 | ALL-ORDS

Healius, formerly Primary Health Care, is an Australian provider of Pathology, Diagnostic and Day Hospital services. It has been listed since 1998.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.355

20 Feb
2025

-0.095

OPEN

$1.42

-6.55%

HIGH

$1.43

2,344,269

LOW

$1.35

TARGET
$1.273 -6.1% downside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
HLS: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 97.9 - 0.4 xxx
DPS (cps) xxx 0.0 13.3 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 10.2% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 6c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-97.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,746.2 M
Book Value Per Share xxxxxxxxxxxxxxx143.3
Net Operating Cash Flow xxxxxxxxxxxxxxx237.8 M
Net Profit Margin xxxxxxxxxxxxxxx-36.42 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-49.94 %
Return on Invested Capital xxxxxxxxxxxxxxx-23.66 %
Return on Assets xxxxxxxxxxxxxxx-19.17 %
Return on Equity xxxxxxxxxxxxxxx-49.94 %
Return on Total Capital xxxxxxxxxxxxxxx2.22 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx186.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx271 M
Long Term Debt xxxxxxxxxxxxxxx1,327 M
Total Debt xxxxxxxxxxxxxxx1,598 M
Goodwill - Gross xxxxxxxxxxxxxxx1,297 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx60 M
Price To Book Value xxxxxxxxxxxxxxx1.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx64.0 M
Capex % of Sales xxxxxxxxxxxxxxx3.67 %
Cost of Goods Sold xxxxxxxxxxxxxxx1,416 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx265 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx3 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.3

No. Of Recommendations

4
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

3

xxxxxxx xx xxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

18/11/2024

3

Neutral

$1.35

-0.37%

Management's expectation for 1H Pathology earnings fell -81% short of Macquarie's forecast, as investments in revenue growth, elevated labour costs, and inflationary pressures weighed on performance.

Healius targets a high-single-digit percentage margin for Pathology and expects a material increase in 2H25, driven by a 1H/2H volume skew and benefits from strategic initiatives, notes the analyst.

Macquarie maintains a Neutral rating and lowers the target price to $1.35 from $1.60, reflecting reduced earnings forecasts and the removal of Lumus Imaging earnings following the division's sale.

FORECAST
Macquarie forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.50 cents.
Macquarie forecasts a full year FY26 dividend of 3.00 cents and EPS of 3.00 cents.

Ord Minnett

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

21/11/2024

4

Downgrade to Underweight from Neutral

$1.25

-7.75%

The Healius AGM revealed a downgrade in the outlook for the Pathology division, with no details provided on the margin deterioration, notes Jarden.

The recent sale of Lumus Imaging, expected to complete in early 2H25, leaves management focusing on remaining operations. Stranded costs from the sale and potential funding cuts pose challenges to the earnings outlook, suggest Jarden.

Management intends to return proceeds from the Lumus sale to shareholders via a special dividend, unlocking $160m in franking credits.

The broker downgrades FY25-27 EPS forecasts by -88.7%, -47.9%, and -42.7%, respectively, and lowers the target price to $1.25 from $1.67. The rating is downgraded to Underweight from Neutral.

FORECAST
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.30 cents.
Jarden forecasts a full year FY26 dividend of 1.70 cents and EPS of 2.90 cents.
Access Extra Coverage Research History >

HLS STOCK CHART

FNArena News on HLS

1
Rudi Interviewed: Turning Laggards Into Winners

Feb 17 2025 - Rudi's View
2
Next Week At A Glance -17-21 Feb 2025

Feb 14 2025 - Weekly Reports
3
Rudi’s View: AGL Energy, Bega Cheese, BRG, Harvey Norman, Imdex & Superloop

Feb 06 2025 - Rudi's View
4
Rudi’s View: Earnings Optimism On The Rise

Feb 05 2025 - Rudi's View
5
Rudi’s View: Cochlear, Guzman y Gomez, SiteMinder, Wesfarmers & Xero

Jan 30 2025 - Rudi's View

Latest Healthcare services News

1
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
2
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
3
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
4
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
5
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
6
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
7
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
8
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
9
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
10
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia